[en] BACKGROUND: Medically managed tricuspid regurgitation (TR) has detrimental outcomes. Transcatheter tricuspid valve interventions (TTVIs) represent an alternative to surgery in high-risk patients; however, only early experiences exist. AIM: The aim of this study was to analyze the clinical and echocardiographic outcomes of TTVI. METHODS: MEDLINE, ISI Web of Science, and SCOPUS databases were searched for studies published up to June 2021. Studies reporting data on outcome post-TTVIs were included. This study was designed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) requirements. The primary endpoint was all-cause mortality at 30-day and 1-year post-TTVI. RESULTS: Out of 2,718 studies, 27 were included. Notably, 30-day and 1-year all-cause mortalities were 5% (95% confidence interval [CI]: 4-8%, p < 0.001) and 25% (95% CI: 12-45%, p = 0.016). Procedural success was associated with a 58% risk reduction in 1-year mortality vs. lack thereof (odds ratio 0.42, 95% CI: 0.27-0.66, p < 0.001). TTVI is associated with a significant reduction in TR severity (TR EROA, mean difference [MD] 0.31 cm(2); 95% CI: 0.23-0.39 cm(2), p < 0.001; regurgitant volume, MD 23.54 ml; 95% CI: 17.4-29.68 ml, p = 0.03) and increase in forward stroke volume (FSV, MD 3.98 ml; 95% CI: 0.11-7.86 ml, p = 0.04). CONCLUSION: TTVI significantly reduces TR severity and increases FSV and is associated with improved survival at 1 year compared with patients without procedural success. Long-term outcomes compared with medical therapy await the results of ongoing pivotal trials; nonetheless, TTVIs appear to be a promising alternative to surgery for TR.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Sannino, Anna; The Heart Hospital Baylor Plano, Plano, TX, United States. ; Department of Advanced Biomedical Sciences, University Federico II, Naples,
Ilardi, Federica; Department of Advanced Biomedical Sciences, University Federico II, Naples, ; Mediterranea Cardiocentro, Naples, Italy.
Hahn, Rebecca T; Division of Cardiology, Columbia University Irving Medical Center, New York, NY,
Lancellotti, Patrizio ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie ; Department of Cardiology and Radiology, GIGA Cardiovascular Sciences, CHU ; Gruppo Villa Maria Care and Research, Lugo, Italy.
Lurz, Philipp; Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of
Smith, Robert L; The Heart Hospital Baylor Plano, Plano, TX, United States.
Esposito, Giovanni; Department of Advanced Biomedical Sciences, University Federico II, Naples,
Grayburn, Paul A; The Heart Hospital Baylor Plano, Plano, TX, United States.
Language :
English
Title :
Clinical and Echocardiographic Outcomes of Transcatheter Tricuspid Valve Interventions: A Systematic Review and Meta-Analysis.
Otto CM Nishimura RA Bonow RO Carabello BA Erwin JP Gentile F et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. (2021) 143:e72–e227. 10.1161/CIR.000000000000092333332150
Vieitez JM Monteagudo JM Mahia P Perez L Lopez T Marco I et al. New insights of tricuspid regurgitation: a large-scale prospective cohort study. Eur Heart J Cardiovasc Imaging. (2020) 22:196–202. 10.1093/ehjci/jeaa20533704454
Muraru D Guta AC Ochoa-Jimenez RC Bartos D Aruta P Mihaila S et al. Functional regurgitation of atrioventricular valves and atrial fibrillation: an elusive pathophysiological link deserving further attention. J Am Soc Echocardiogr. (2020) 33:42–53. 10.1016/j.echo.2019.08.01631685293
Wang N Fulcher J Abeysuriya N McGrady M Wilcox I Celermajer D et al. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. Eur Heart J. (2019) 40:476–84. 10.1093/eurheartj/ehy64130351406
Vahanian A Beyersdorf F Praz F Milojevic M Baldus S Bauersachs J et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. (2021) 43:561–632. 10.1093/ejcts/ezac20935636831
Alqahtani F Berzingi CO Aljohani S Hijazi M Al-Hallak A Alkhouli M. Contemporary trends in the use and outcomes of surgical treatment of tricuspid regurgitation. J Am Heart Assoc. (2017) 6:e007597. 10.1161/JAHA.117.00759729273638
Dreyfus J Flagiello M Bazire B Eggenspieler F Viau F Riant E et al. Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes. Eur Heart J. (2020) 41:4304–17. 10.1093/eurheartj/ehaa64332974668
Nishimura RA Otto CM Bonow RO Carabello BA Erwin JP Fleisher LA et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. (2017) 135:e1159–e95. 10.1161/CIR.000000000000050328315732
Moher D Liberati A Tetzlaff J Altman DG Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. (2010) 8:336–41. 10.1016/j.ijsu.2010.02.00720171303
Taramasso M Alessandrini H Latib A Asami M Attinger-Toller A Biasco L et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the international TriValve registry. JACC Cardiovasc Interv. (2019) 12:155–65. 10.1016/j.jcin.2018.10.02230594510
Sannino A Hahn RT Leipsic J Mack MJ Grayburn PA. Meta-analysis of incidence, predictors and consequences of clinical and subclinical bioprosthetic leaflet thrombosis after transcatheter aortic valve implantation. Am J Cardiol. (2020) 132:106–13. 10.1016/j.amjcard.2020.07.01832773221
Higgins JP Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. (2004) 23:1663–82. 10.1002/sim.175215160401
Ali FM Ong G Edwards J Connelly KA Fam NP. Comparison of transcatheter tricuspid valve repair using the MitraClip NTR and XTR systems. Int J Cardiol. (2021) 327:156–62. 10.1016/j.ijcard.2020.11.07333301831
Asmarats L Perlman G Praz F Hensey M Chrissoheris MP Philippon F et al. Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of Severe Tricuspid Regurgitation: Insights From the First-in-Human Experience. JACC Cardiovasc Interv. (2019) 12:1438–47. 10.1016/j.jcin.2019.04.03831395213
Besler C Orban M Rommel KP Braun D Patel M Hagl C et al. Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge-to-edge repair. JACC Cardiovasc Interv. (2018) 11:1119–28. 10.1016/j.jcin.2018.05.00229929631
Braun D Orban M Orban M Hagl C Massberg S Nabauer M et al. Transcatheter edge-to-edge repair for severe tricuspid regurgitation using the triple-orifice technique versus the bicuspidalization technique. JACC Cardiovasc Interv. (2018) 11:1790–2. 10.1016/j.jcin.2018.05.04930170957
Braun D Rommel KP Orban M Karam N Brinkmann I Besler C et al. Acute and short-term results of transcatheter edge-to-edge repair for severe tricuspid regurgitation using the MitraClip XTR system. JACC Cardiovasc Interv. (2019) 12:604–5. 10.1016/j.jcin.2018.11.02830898258
Cai S Bowers N Dhoot A Ho EC Ong G Eckstein J et al. Natural history of severe tricuspid regurgitation: Outcomes after transcatheter tricuspid valve intervention compared to medical therapy. Int J Cardiol. (2020) 320:49–54. 10.1016/j.ijcard.2020.07.01832682962
Campelo-Parada F Perlman G Philippon F Ye J Thompson C Bedard E et al. First-in-Man Experience of a Novel Transcatheter Repair System for Treating Severe Tricuspid Regurgitation. J Am Coll Cardiol. (2015) 66:2475–83. 10.1016/j.jacc.2015.09.06826653620
Davidson CJ Lim DS Smith RL Kodali SK Kipperman RM Eleid MF et al. Early Feasibility Study of Cardioband Tricuspid System for Functional Tricuspid Regurgitation: 30-Day Outcomes. JACC Cardiovasc Interv. (2021) 14:41–50. 10.1016/j.jcin.2020.10.01733413863
Dreger H Mattig I Hewing B Knebel F Lauten A Lembcke A et al. Treatment of Severe TRIcuspid Regurgitation in Patients with Advanced Heart Failure with CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL): a randomised controlled trial. EuroIntervention. (2020) 15:1506–13. 10.4244/EIJ-D-19-0090131929100
Fam NP Braun D von Bardeleben RS Nabauer M Ruf T Connelly KA et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. (2019) 12:2488–95. 10.1016/j.jcin.2019.09.04631857018
Fam NP von Bardeleben RS Hensey M Kodali SK Smith RL Hausleiter J et al. Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. (2021) 14:501–11. 10.1016/j.jcin.2020.11.04533582084
Hahn RT Kodali S Fam N Bapat V Bartus K Rodes-Cabau J et al. Early multinational experience of transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation. JACC Cardiovasc Interv. (2020) 13:2482–93. 10.1016/j.jcin.2020.07.00833153565
Hahn RT Meduri CU Davidson CJ Lim S Nazif TM Ricciardi MJ et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results. J Am Coll Cardiol. (2017) 69:1795–806. 10.1016/j.jacc.2017.01.05428385308
Kitamura M Fam NP Braun D Ruf T Sugiura A Narang A et al. 12-Month outcomes of transcatheter tricuspid valve repair with the PASCAL system for severe tricuspid regurgitation. Catheter Cardiovasc Interv. (2021) 97:1281–9. 10.1002/ccd.2958333660364
Kodali S Hahn RT Eleid MF Kipperman R Smith R Lim DS et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol. (2021) 77:345–56. 10.1016/j.jacc.2020.11.04733509390
Lauten A Figulla HR Unbehaun A Fam N Schofer J Doenst T et al. Interventional treatment of severe tricuspid regurgitation: early clinical experience in a multicenter, observational, first-in-man study. Circ Cardiovasc Interv. (2018) 11:e006061. 10.1161/CIRCINTERVENTIONS.117.00606129445001
Lurz P Besler C Noack T Forner AF Bevilacqua C Seeburger J et al. Transcatheter treatment of tricuspid regurgitation using edge-to-edge repair: procedural results, clinical implications and predictors of success. EuroIntervention. (2018) 14:e290–e7. 10.4244/EIJ-D-17-0109129633941
Mehr M Taramasso M Besler C Ruf T Connelly KA Weber M et al. 1-Year outcomes after edge-to-edge valve repair for symptomatic tricuspid regurgitation: results from the trivalve registry. JACC Cardiovasc Interv. (2019) 12:1451–61. 10.1016/j.jcin.2019.04.01931395215
Nickenig G Kowalski M Hausleiter J Braun D Schofer J Yzeiraj E et al. Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge mitraclip technique. Circulation. (2017) 135:1802–14. 10.1161/CIRCULATIONAHA.116.02484830927530
Nickenig G Weber M Lurz P von Bardeleben RS Sitges M Sorajja P et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. (2019) 394:2002–11. 10.1016/S0140-6736(19)32600-531708188
Nickenig G Weber M Schueler R Hausleiter J Nabauer M von Bardeleben RS et al. 6-Month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. J Am Coll Cardiol. (2019) 73:1905–15. 10.1016/j.jacc.2019.01.06230999993
Orban M Rommel KP Ho EC Unterhuber M Pozzoli A Connelly KA et al. Transcatheter edge-to-edge tricuspid repair for severe tricuspid regurgitation reduces hospitalizations for heart failure. JACC Heart Fail. (2020) 8:265–76. 10.1016/j.jchf.2019.12.00632241534
Perlman G Praz F Puri R Ofek H Ye J Philippon F et al. Transcatheter tricuspid valve repair with a new transcatheter coaptation system for the treatment of severe tricuspid regurgitation: 1-year clinical and echocardiographic results. JACC Cardiovasc Interv. (2017) 10:1994–2003. 10.1016/j.jcin.2017.06.03628780036
Perlman GY Dvir D. Treatment of tricuspid regurgitation with the FORMA repair system. Front Cardiovasc Med. (2018) 5:140. 10.3389/fcvm.2018.0014031395213
Rommel KP Besler C Noack T Blazek S von Roeder M Fengler K et al. Physiological and clinical consequences of right ventricular volume overload reduction after transcatheter treatment for tricuspid regurgitation. JACC Cardiovasc Interv. (2019) 12:1423–34. 10.1016/j.jcin.2019.02.04231326430
Ruf TF Hahn RT Kreidel F Beiras-Fernandez A Hell M Gerdes P et al. Short-term clinical outcomes of transcatheter tricuspid valve repair with the third-generation MitraClip XTR system. JACC Cardiovasc Interv. (2021) 14:1231–40. 10.1016/j.jcin.2021.03.03334112460
Sugiura A Vogelhuber J Ozturk C Schwaibold Z Reckers D Goto T et al. PASCAL versus MitraClip-XTR edge-to-edge device for the treatment of tricuspid regurgitation: a propensity-matched analysis. Clin Res Cardiol. (2021) 110:451–9. 10.1007/s00392-020-01784-w33313975
Benfari G Antoine C Miller WL Thapa P Topilsky Y Rossi A. et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation. (2019) 140:196–206. 10.1161/CIRCULATIONAHA.118.03894631117814
Zack CJ Fender EA Chandrashekar P Reddy YNV Bennett CE Stulak JM et al. National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol. (2017) 70:2953–60. 10.1016/j.jacc.2017.10.03929969002
Kawsara A Alqahtani F Nkomo VT Eleid MF Pislaru SV Rihal CS et al. Determinants of morbidity and mortality associated with isolated tricuspid valve surgery. J Am Heart Assoc. (2021) 10:e018417. 10.1161/JAHA.120.01841733399012
Hamandi M Smith RL Ryan WH Grayburn PA Vasudevan A George TJ et al. Outcomes of isolated tricuspid valve surgery have improved in the modern era. Ann Thorac Surg. (2019) 108:11–5. 10.1016/j.athoracsur.2019.03.00430951698
Nath J Foster E Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. (2004) 43:405–9. 10.1016/j.jacc.2003.09.03615013122
Chorin E Rozenbaum Z Topilsky Y Konigstein M Ziv-Baran T Richert E et al. Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc Imaging. (2020) 21:157–65. 10.1093/ehjci/jez21633157062
Wong WK Chen SW Chou AH Lee HA Cheng YT Tsai FC et al. Late outcomes of valve repair versus replacement in isolated and concomitant tricuspid valve surgery: a nationwide cohort study. J Am Heart Assoc. (2020) 9:e015637. 10.1161/JAHA.119.01563732301369
Vassileva CM Shabosky J Boley T Markwell S Hazelrigg S. Tricuspid valve surgery: the past 10 years from the Nationwide Inpatient Sample (NIS) database. J Thorac Cardiovasc Surg. (2012) 143:1043–9. 10.1016/j.jtcvs.2011.07.00421872283
Kar S Mack MJ Lindenfeld J Abraham WT Asch FM Weissman NJ et al. Relationship between residual mitral regurgitation and clinical and quality-of-life outcomes after transcatheter and medical treatments in heart failure: COAPT trial. Circulation. (2021) 144:426–37. 10.1161/CIRCULATIONAHA.120.05306134039025
O'Neill BP Negrotto S Yu D Lakhter V Depta J McCabe JM et al. Caval valve implantation for tricuspid regurgitation: insights from the united states caval valve registry. J Invasive Cardiol. (2020) 32:470–5.33087585
Toggweiler S De Boeck B Brinkert M Buhmann R Bossard M Kobza R et al. First-in-man implantation of the Tricento transcatheter heart valve for the treatment of severe tricuspid regurgitation. EuroIntervention. (2018) 14:758–61. 10.4244/EIJ-D-18-0044029969434
Lauten A Dreger H Schofer J Grube E Beckhoff F Jakob P et al. Caval valve implantation for treatment of severe tricuspid regurgitation. J Am Coll Cardiol. (2018) 71:1183–4. 10.1016/j.jacc.2017.12.05631929100
Sugiura A Tanaka T Kavsur R Oeztuerk C Vogelhuber J Wilde N et al. Leaflet configuration and residual tricuspid regurgitation after transcatheter edge-to-edge tricuspid repair. JACC Cardiovasc Interv. (2021) 14:2260–70. 10.1016/j.jcin.2021.07.04834424200
Taramasso M Gavazzoni M Pozzoli A Dreyfus GD Bolling SF George I et al. Tricuspid regurgitation: predicting the need for intervention, procedural success, and recurrence of disease. JACC Cardiovasc Imaging. (2019) 12:605–21. 10.1016/j.jcmg.2018.11.03430947904
Fortuni F Butcher SC Dietz MF van der Bijl P Prihadi EA De Ferrari GM et al. Right ventricular-pulmonary arterial coupling in secondary tricuspid regurgitation. Am J Cardiol. (2021) 148:138–45. 10.1016/j.amjcard.2021.02.03733667451
